Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
October 1, 2026 · via Europe PMC
Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy.
McCrary LM, Curtis MR, Kelly JC, +6 more, Marks LR.
AI summary — for doctors, generated from the abstract only
In a small real-world series, glecaprevir-pibrentasvir given during pregnancy produced virologic response in all patients who completed treatment, with no maternal or neonatal safety concerns reported.
What was studied
A case-series report of the authors' experience treating hepatitis C virus infection with glecaprevir-pibrentasvir (GLE/PIB) during pregnancy in 14 patients, since no trial or real-world data previously existed for this regimen in pregnancy.
Key findings
- 14 pregnant patients received prenatal GLE/PIB
- Ten patients completed treatment
- All of those who completed treatment achieved virologic response by or at delivery
- No maternal or neonatal safety concerns were reported
Clinical relevance
Guidelines endorse antenatal hepatitis C treatment after shared decision making, so even small real-world experience with a specific regimen helps clinicians and patients weigh that option.
Who should care
Limitations
The abstract is very short and gives no detail on the four patients who did not complete treatment, follow-up length, or infant outcomes. The sample is only 14 patients with no comparison group, so rare adverse events cannot be excluded.
Early real-world data are reassuring for GLE/PIB in pregnancy, but the numbers are too small to be conclusive.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Guidelines endorse antenatal hepatitis C virus treatment following shared decision making. No clinical trial or real-world data exist for glecaprevir-pibrentasvir (GLE/PIB). We report our experience with prenatal GLE/PIB in 14 patients. Ten patients completed treatment; all achieved virologic response by or at delivery, with no maternal or neonatal safety concerns.
DOI
10.1093/cid/ciag422
PMID
42578822
PMCID
PMC13644863
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed